Dermata Therapeutics, Inc.
DRMANASDAQHealthcareBiotechnology
Previous close
$1.42
+$0.04 · +2.90%
DRMA company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
47
Fair Value
Momentum
33
Weakening
Sentiment
33
Bearish
Risk resilience
28
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteDermata Therapeutics, Inc. operates as a clinical-stage biotechnology enterprise, concentrating its efforts on discovering, advancing, and bringing to market novel pharmaceutical treatments designed to address various medical and cosmetic skin ailments. The company's principal experimental drug, DMT310, has successfully finished Phase IIb clinical trials for moderate-to-severe acne and completed a Phase Ib proof-of-concept study for mild-to-moderate psoriasis. Furthermore, DMT310 is presently undergoing Phase 2 clinical evaluation for moderate-to-severe rosacea. Dermata is also progressing with DMT410, which has concluded Phase Ib proof-of-concept trials aimed at managing hyperhidrosis and other aesthetic concerns. Established in 2014, the firm maintains its headquarters in San Diego, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Gerald T. Proehl
- Listed since
- Aug 13, 2021
- Employees
- 9
Market position
Day range
Current $1.42
52-week range
Current $1.42
- Open
- $1.38
- Previous close
- $1.38
- Volume
- 230.39K
- 3.13× average
- Average volume
- 73.51K
- Average daily volume
- Market cap
- 967.81K USD
- Beta
- 0.66
- Market reference 1
- 50-day average
- $1.2782
- +11.09% above average
- 200-day average
- $1.6819
- -15.57% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- P/E (TTM)
- -0.32×
- P/B (TTM)
- 1.64×
- P/S (TTM)
- 0×
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
Financial health
- Debt / equity
- 0×
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 2.93M USD | 8.2M USD | 4.07M USD | 5.65M USD | 3.46M USD |
| Selling, general, and administrative | 4.84M USD | 4.31M USD | 3.97M USD | 4.02M USD | 4.4M USD |
| Operating expenses | 7.77M USD | 12.51M USD | 8.04M USD | 9.67M USD | 7.86M USD |
| Interest income | 215.04K USD | 225.78K USD | 247.22K USD | 63.57K USD | 45.61 USD |
| Interest expense | — | — | — | −63.57K USD | 45.61K USD |
| Depreciation and amortization | — | — | 8.04M USD | — | — |
| Operating income | −7.77M USD | −12.51M USD | −8.04M USD | −9.67M USD | −7.86M USD |
| Net income | −7.56M USD | −12.29M USD | −7.8M USD | −9.61M USD | −7.9M USD |
Company facts updated Aug 24, 2026.
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$6.00
322.54% upsideCorporate actions
Corporate action history
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Aug 1, 2025 | 1:10 | — | — |
Stock split | May 16, 2024 | 1:15 | — | — |
Stock split | Mar 14, 2023 | 1:16 | — | — |
Effective Aug 1, 2025
1:10
Effective May 16, 2024
1:15
Effective Mar 14, 2023
1:16
DRMA peers
Continue in GoAI
Research DRMAresearch.disclaimer